ASND
Ascendis Pharma AS
227.90$
+0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | +3,182.4% | -111.1% | – | – | |
| – | +4.9% | -10.0% | -2.0% | -0.3% | +2.3% | +1.6% | -5.2% | -6.7% | +18.9% | -10.2% | +8.3% | – | |
| – | -7.4% | +8.6% | +50.7% | -0.2% | +0.8% | -2.5% | +17.5% | +2.0% | -2.2% | +1.3% | -2.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -149.9% | – | -187.2% | – | +56.6% | -276.0% | – | – | |
| – | -93.5% | +215.9% | +71.9% | +36.5% | -18.0% | +83.6% | +517.1% | -98.8% | +6,118.8% | +137.8% | -58.7% | – | |
| – | -70.1% | +7.6% | -91.5% | -182.7% | -23.7% | +83.1% | +517.1% | -98.8% | +6,118.8% | +108.3% | -58.4% | – | |
| – | – | -100.0% | – | – | – | – | -100.0% | – | -84.7% | +58,461.9% | -1.2% | – | |
| – | – | – | – | – | -102.2% | +4.0% | +79.0% | +19.8% | +4.0% | +25.5% | -5.1% | – | |
| – | -104.2% | – | -113.3% | – | -100.0% | -20,817.2% | – | +456.6% | -78.5% | -548.0% | +24.6% | – | |
| – | -204.4% | – | – | – | -118.0% | – | – | – | +70.2% | -172.0% | – | – | |
| – | – | – | – | – | – | – | – | – | +3,108.3% | -123.3% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.